Metastatic Uveal Melanoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Metastatic Uveal Melanoma – Pipeline Review, H2 2016’, provides an overview of the Metastatic Uveal Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Uveal Melanoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Uveal Melanoma

The report reviews pipeline therapeutics for Metastatic Uveal Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Metastatic Uveal Melanoma therapeutics and enlists all their major and minor projects

The report assesses Metastatic Uveal Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Metastatic Uveal Melanoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Metastatic Uveal Melanoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metastatic Uveal Melanoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bellicum Pharmaceuticals Inc

Celldex Therapeutics Inc

Eli Lilly and Company

Novartis AG

Spectrum Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Metastatic Uveal Melanoma Overview 6

Therapeutics Development 7

Pipeline Products for Metastatic Uveal Melanoma - Overview 7

Pipeline Products for Metastatic Uveal Melanoma - Comparative Analysis 8

Metastatic Uveal Melanoma - Therapeutics under Development by Companies 9

Metastatic Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes 10

Metastatic Uveal Melanoma - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Metastatic Uveal Melanoma - Products under Development by Companies 13

Metastatic Uveal Melanoma - Products under Investigation by Universities/Institutes 14

Metastatic Uveal Melanoma - Companies Involved in Therapeutics Development 15

Bellicum Pharmaceuticals Inc 15

Celldex Therapeutics Inc 16

Eli Lilly and Company 17

Novartis AG 18

Spectrum Pharmaceuticals Inc 19

Metastatic Uveal Melanoma - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

alpelisib - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

BPX-701 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

emibetuzumab - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

glembatumumab vedotin - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

KCN-1 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

LXS-196 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

merestinib - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

sotrastaurin acetate - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

vincristine sulfate - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Metastatic Uveal Melanoma - Dormant Projects 51

Metastatic Uveal Melanoma - Discontinued Products 52

Metastatic Uveal Melanoma - Product Development Milestones 53

Featured News & Press Releases 53

Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016 53

Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC 53

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Tables

List of Tables

Number of Products under Development for Metastatic Uveal Melanoma, H2 2016 7

Number of Products under Development for Metastatic Uveal Melanoma – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Metastatic Uveal Melanoma – Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 15

Metastatic Uveal Melanoma – Pipeline by Celldex Therapeutics Inc, H2 2016 16

Metastatic Uveal Melanoma – Pipeline by Eli Lilly and Company, H2 2016 17

Metastatic Uveal Melanoma – Pipeline by Novartis AG, H2 2016 18

Metastatic Uveal Melanoma – Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Metastatic Uveal Melanoma – Dormant Projects, H2 2016 51

Metastatic Uveal Melanoma – Discontinued Products, H2 2016 52

List of Figures

List of Figures

Number of Products under Development for Metastatic Uveal Melanoma, H2 2016 7

Number of Products under Development for Metastatic Uveal Melanoma – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Targets, H2 2016 21

Number of Products by Stage and Targets, H2 2016 21

Number of Products by Top 10 Mechanism of Actions, H2 2016 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Types, H2 2016 27

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports